Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 60INDUSTRY 27NIH 8OTHER_GOV 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Neoplasms, Plasma Cell 1Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1Colorectal Neoplasms 1

Interventions

Rituximab 3Vincristine 2Prednisone 2Epirubicin 2Cyclophosphamide 2zanubrutinib 1liposomal doxorubicin 1ibrutinib 1durvalumab 1Vinorelbine 1Thalidomide 1Radiotherapy 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Mitoxantrone 1Methotrexate 1Lenalidomide 1Human Papillomavirus Recombinant Vaccine nonavalent 1Dexamethasone 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Lymphoma, Large B-Cell, Diffuse × Lenalidomide × Clear all
NCT04214626 2025-11-19

R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma

Henan Cancer Hospital

Phase 2 Completed
60 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡